BPC-157 for Hair Loss: Does Injecting it Into the Scalp Actually Work?
Published by AmpleLab Research
Scalp injections of BPC-157 have been circulating in hair loss and biohacking communities, usually on the assumption that injecting directly into the scalp delivers a concentrated, localised dose to the follicles. This article checks two separate things: whether that assumption about injection site actually holds up pharmacologically, and whether there's any real hair-specific evidence behind the practice at all. This is an evidence review, not a protocol, we won't be covering dosing, reconstitution, or injection technique.
Worth stating upfront: BPC-157 is not an approved drug in the UK or US, and AmpleLab doesn't sell or recommend it. It's reviewed here because people are asking about it, not because we're endorsing its use.
Largely no, and this is the actual pharmacokinetics, not a theoretical objection.
In rats and beagle dogs, BPC-157 showed an elimination half-life under 30 minutes following intramuscular or intravenous administration, with linear pharmacokinetics across doses. Absolute bioavailability after intramuscular injection was approximately 14-19% in rats and 45-51% in dogs. The compound was cleared primarily through urine and bile, consistent with systemic distribution and rapid processing rather than a substance that stays put where it's injected.
Caveat: Animal data, not human; human pharmacokinetics for BPC-157 haven't been formally established. These bioavailability figures are also considerably lower than the "80-95%" figures repeated across some commercial peptide sites, which we could not trace to this or any other verifiable source.
A subcutaneous or intramuscular injection deposits the compound into local tissue, where it's absorbed into nearby capillaries and lymphatics before entering general circulation. There is a real, brief window, roughly the first 15-30 minutes, where local tissue concentration near the injection site is higher than elsewhere, before the compound distributes and equilibrates systemically and is then rapidly cleared given the short half-life above. That's a genuine pharmacological nuance, injection site isn't completely irrelevant in the first half hour, but it's a transient head start, not a sustained, concentrated local reservoir. Once systemic distribution occurs, which happens quickly given the short half-life, the compound is circulating and being cleared throughout the body regardless of where it went in.
In practical terms: injecting into the scalp specifically doesn't create a sustained, scalp-concentrated dose in any meaningful way beyond that initial diffusion window. A person injecting into the abdomen and a person injecting into the scalp are, after the first half hour or so, likely exposing their whole body, including the scalp, to a broadly similar systemic concentration profile, not fundamentally different local outcomes at the follicle level.
No, and this is worth being direct about. We covered BPC-157's genuine evidence base in our article on GHK-Cu, BPC-157, and TB-500: a 2025 systematic review found only three human pilot studies exist for BPC-157 across any indication, covering knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics. None of them involved hair or scalp tissue. The animal research is broader, gut healing, tendon repair, general wound healing, but hair-specific animal studies are similarly absent from the published literature.
The hair-growth case being made for BPC-157 online is built entirely by extrapolation from its studied properties elsewhere, angiogenesis promotion via VEGFR2 activation, anti-inflammatory signalling, general wound-healing activity, reasoned across to hair follicle biology on the logic that improved blood supply and reduced inflammation would plausibly help a struggling follicle. That's a coherent hypothesis. It is not a tested one.
We also want to flag something specific: a claim circulates online describing a mouse scalp-injection study and a 30-patient, six-month human trial showing increased hair density with BPC-157. We looked for the underlying study and could not locate it anywhere in the published or preprint literature, and it's inconsistent with the systematic review above, which found no hair-related human studies of any kind. We'd treat this specific claim as unverified rather than repeat it as fact.
BPC-157 is not an approved drug in the UK, US, or EU, and health and wellness products containing it have been specifically flagged by supplement safety bodies as containing an unapproved, prohibited substance. It doesn't have the regulatory standing of a licensed medicine or the safety review history of an established cosmetic ingredient, a distinction covered in more depth in our article on GHK-Cu topical vs injection, which covers the broader research-chemical peptide landscape.
The honest position
Injecting BPC-157 into the scalp doesn't produce a sustained, concentrated local dose the way the practice is often described; the compound is absorbed and distributed systemically within the same short timeframe as injecting it anywhere else on the body, with only a brief local concentration advantage in the first half hour. Separately, and more importantly, there is no published hair-specific research, human or animal, behind BPC-157's use for hair loss at all. The entire rationale is extrapolated from unrelated tissue research. That's not the same as evidence, and a specific "clinical study" claim circulating for this use case doesn't appear to be real.
Does injecting BPC-157 into the scalp target the follicles more than injecting elsewhere?
Only marginally, and only briefly. Published pharmacokinetic data shows rapid systemic absorption and a short half-life, meaning the compound distributes throughout the body within roughly 15-30 minutes regardless of injection site. There's a small local concentration advantage during that initial window, not a sustained, scalp-specific reservoir.
Is there a real clinical study showing BPC-157 regrows hair?
We couldn't verify one. A systematic review of BPC-157's human evidence found only three pilot studies total, for knee pain, interstitial cystitis, and IV safety, none related to hair. A specific "30-patient" hair study referenced in some online content doesn't appear in the published or preprint literature that we could locate.
Why do people believe scalp injection works better if the pharmacology doesn't support it?
Likely a reasonable-sounding but incorrect intuition, that injecting near a target tissue concentrates the effect there, which is true for some drugs and delivery contexts but doesn't hold for a small, rapidly systemic, short-half-life peptide like BPC-157. The assumption isn't unreasonable on its face; it just doesn't match what the actual pharmacokinetic data shows for this specific compound.
Does AmpleLab sell or recommend BPC-157?
No. We produce topical cosmetic formulations. This article reports on the published literature and pharmacology for context; it isn't a recommendation, protocol, or endorsement.
This article is provided for educational purposes and does not constitute medical advice, and is not a guide to injectable peptide use. BPC-157 is not approved for human use in the UK or US. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.